Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIETI, RUTH SOPHIA | 1 | 45.2% | +73.6% |
| GALSTER, SAMUEL LEONARD | 1 | 53.8% | +39.1% |
| MCMILLIAN, KARA RENITA | 1 | 30.6% | +37.9% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 57.4% | +45.0% |
| ELENISTE, PIERRE PAUL | 1 | 38.5% | +30.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504781 | Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy | ARIETI, RUTH SOPHIA | 162d overdue |
| 17293929 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | ELENISTE, PIERRE PAUL | 117d overdue |
| 17788551 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | RZECZYCKI, PHILLIP MATTHEW | 19d overdue |
| 18288057 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | GALSTER, SAMUEL LEONARD | 9d overdue |
| 18284941 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | MCMILLIAN, KARA RENITA | 41d |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1693 | 1 |
| 1623 | 1 |
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18504781 | Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy | ARIETI, RUTH SOPHIA | 1635 | Other | Final Rejection | 162d overdue | Pending | Nov 08, 2023 |
| 18288057 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | 9d overdue | Pending | Oct 24, 2023 |
| 18284941 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | MCMILLIAN, KARA RENITA | 1623 | §102 | Non-Final OA | 41d | Pending | Sep 29, 2023 |
| 17788551 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Final Rejection | 19d overdue | Pending | Jun 23, 2022 |
| 17293929 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | ELENISTE, PIERRE PAUL | 1622 | §112 | Non-Final OA | 117d overdue | Pending | May 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial